All In Biotech

NDA 021896 · Gilead

Emtriva

Emtricitabine · Oral · Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor

Priority review

Last checked: Nov 20, 2026Latest source record: Dec 10, 2018 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2005

Sep 28, 2005

Approved uses

3

Original approval plus efficacy supplements

Registered trials

684

198 Phase 3, 28 recruiting

FAERS reports

7,211

6,881 serious, 901 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

Boxed warning

WARNING: POSTTREATMENT ACUTE EXACERBATION OF HEPATITIS B Severe acute exacerbations of hepatitis B (HBV) have been reported in patients who are coinfected with HIV-1 and HBV and have discontinued EMTRIVA. Hepatic function should be monitored closely with both clinical and laboratory follow-up for at least several months in patients who are coinfected with HIV-1 and HBV and discontinue EMTRIVA. If appropriate, initiation of anti-hepatitis B therapy may be warranted [see Warnings and Precautions (5.1) ]. WARNING: POSTTREATMENT ACUTE EXACERBATION OF HEPATITIS B See full prescribing information for complete boxed warning . Severe acute exacerbations of Hepatitis B (HBV) have been reported in patients coinfected with HIV-1 and HBV who have discontinued EMTRIVA. Hepatic function should be monitored closely in patients coinfected with HIV-1 and HBV who discontinue EMTRIVA. If appropriate,...

What it is approved for

From the label in effect Nov 6, 2026.

EMTRIVA ® is indicated in combination with other antiretroviral agents for the treatment of HIV-1 infection. EMTRIVA, a nucleoside analog HIV-1 reverse transcriptase inhibitor, is indicated in combination with other antiretroviral agents for the treatment of HIV-1 infection. ( 1 )

Mechanism: Emtricitabine is an antiretroviral drug [see Microbiology (12.4) ].

Therapeutic areas: Infectious disease and vaccines · Rare and genetic disease

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

2 products under this application
  • EMTRIVA · EMTRICITABINE 10MG/ML · SOLUTION, ORAL · Prescription
  • EMTRIVA · EMTRICITABINE 10MG/ML · SOLUTION, ORAL · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Emtricitabine" as an intervention, any sponsor and status, largest first.

All 684 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • drug interaction663
  • foetal exposure during pregnancy622
  • drug resistance437
  • anxiety432
  • virologic failure407
  • drug ineffective331
  • immune reconstitution inflammatory syndrome300
  • off label use279
  • pain264
  • emotional distress239
  • depression235
  • exposure during pregnancy229

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
200481
200595
2006115
2007123
2008154
2009198
2010129
2011141
2012118
2013240
2014245
2015390
2016568
2017582
2018646
2019686
2020709
2021496
2022510
2023396
2024261
2025207
2026121

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

  • To Be Discontinued · updated Jun 17, 2026

    Emtriva, Oral Solution, 10 mg/1 mL (NDC 61958-0602-1). Product expected to be available until March 2027

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Emtriva (Emtricitabine)

2024 spending

$228K

Beneficiaries

114

439 claims

Per beneficiary

$1,999

$14.26 per unit

View as table
YearSpending
2020$5,376,033
2021$1,706,880
2022$542,738
2023$311,936
2024$227,832

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 971 on PubMed

Sponsor: Gilead Sciences

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.